1,25-Dihydroxyvitamin D3 prevented allergic asthma in a rat model by suppressing the expression of inducible nitric oxide synthase
Abstract:The active form of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] regulates calcium homeostasis, immunity, and other physiological processes while its effect in T-helper lymphocyte type 2 models is not very clear. The prevention effect of 1,25(OH)2D3 for allergic asthma in a rat asthma model was investigated. Healthy Wistar rats were randomly divided into four groups: control group, asthma group, drug prevention group, and treatment group. Asthma was induced in rats by sensitization and challenges with ovalbumin (OVA). The drug prevention group and treatment group were given 1,25(OH)2D3 or vitamin D3 on different schedules. The effects of 1,25(OH)2D3 on the development of asthma were analyzed. The airway hyperresponsiveness, the inflammatory cell infiltration in bronchoalveolar lavage (BAL) fluid, and histological changes of lung cells were examined. Nitric oxide production and the expression and activity of induced nitric oxide synthase (iNOS) in the lungs were examined also. Our study showed that 1,25(OH)2D3 reduced the airway inflammatory response in BAL. The concentration of NO and the activity and expression of iNOS in the lungs were decreased in the 1,25(OH)2D3 prevention and treatment groups. The expression of iNOS mRNA and protein levels were dose-dependently attenuated in the presence of 10−13–10−8 mol/L of 1,25(OH)2D3 in alveolar macrophage culture. These findings collectively indicated that 1,25(OH)2D3 lowered many symptoms of inflammatory responses and decreased the expression of iNOS in OVA-induced experimental asthma. 1,25(OH)2D3 could be used as a new therapeutic agent in the treatment of asthma.
Document Type: Research Article
Affiliations: Department of Respiratory Medicine, Shanghai First Hospital, Shanghai Jiao Tong University, Shanghai 200080, China
Publication date: May 1, 2008
More about this publication?
- Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.
The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.
Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
Articles marked "F" offer free full text for personal noncommercial use only.
The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
- Editorial Board
- Information for Authors
- Submit a Paper
- Information for Advertisers
- Reprint Requests
- ingentaconnect is not responsible for the content or availability of external websites